These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23835329)

  • 1. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
    Teff KL; Rickels MR; Grudziak J; Fuller C; Nguyen HL; Rickels K
    Diabetes; 2013 Sep; 62(9):3232-40. PubMed ID: 23835329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 5. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
    Ballon JS; Pajvani UB; Mayer LE; Freyberg Z; Freyberg R; Contreras I; Rosenbaum M; Leibel RL; Lieberman JA
    J Psychopharmacol; 2018 May; 32(5):533-540. PubMed ID: 29444618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
    JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the mechanisms underlying olanzapine-induced insulin resistance.
    Irwin N; Gault VA
    Diabetes; 2013 Sep; 62(9):3022-3. PubMed ID: 23970523
    [No Abstract]   [Full Text] [Related]  

  • 12. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
    Henderson DC; Fan X; Copeland PM; Sharma B; Borba CP; Boxill R; Freudenreich O; Cather C; Evins AE; Goff DC
    J Clin Psychopharmacol; 2009 Apr; 29(2):165-9. PubMed ID: 19512978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
    J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.
    Teff KL; Rickels K; Alshehabi E; Rickels MR
    J Clin Psychopharmacol; 2015 Oct; 35(5):579-82. PubMed ID: 26274045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole for the management of olanzapine-induced weight gain.
    Englisch S; Weinbrenner A; Inta D; Zink M
    Pharmacopsychiatry; 2009 Jul; 42(4):166-7. PubMed ID: 19585397
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
    Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
    J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
    J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.